Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2012 Financial Results
Date:2/27/2013

rking Capital HighlightsAt December 31, 2012, our working capital was $339.4 million compared to $537.3 million at December 31, 2011 as we generated $43 million in cash flow from operations and deployed $180.3 million to repurchase 6.9 million shares during 2012.

Looking ahead in 2013ViroPharma is providing guidance for the year 2013 as a convenience to investors. The following guidance provided by ViroPharma are projections, based upon numerous assumptions, all of which are subject to certain risks and uncertainties. For a discussion of the risks and uncertainties associated with these forward looking statements, please see the Disclosure Notice below.

For the year 2013, ViroPharma expects the following:

  • Worldwide net product sales are expected to be $450 to $475 million;
  • Net North American Cinryze sales are expected to be $390 to $400 million; and
  • Research and development (R&D) and selling, general and administrative (SG&A) expenses are expected to be $240 to $260 million.
  • Non-GAAP DisclosuresThe Company is reporting both GAAP net income (loss) and non-GAAP adjusted results for the three months and year ended December 31, 2012 and 2011. Non-GAAP adjusted net income is GAAP net income (loss) excluding (1) non-cash interest expense, (2) amortization related to intangible assets acquired, (3) share-based compensation expenses, (4) contingent consideration, and (5) certain non-recurring events. Non-GAAP adjusted diluted net income per share reflects the Non-GAAP adjusted net income, after the incremental effect of applying the "if converted" method of accounting to the senior convertible notes, and the diluted shares used in determining our GAAP diluted net income (loss) per share. A reconciliation between GAAP and non-GAAP adjusted measures is provided in the Selected Financial Information – Non-GAAP Financial Measures Reconciliation table included with this release. The Company beli
    '/>"/>

    SOURCE ViroPharma Incorporated
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12

    Related medicine technology :

    1. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
    2. Faruqi & Faruqi, LLP Announces Investigation of ViroPharma Incorporated
    3. ViroPharma To Participate In The JMP Securities Healthcare Conference
    4. Berger & Montague, P.C. Reminds Viropharma Shareholders That The Deadline To Petition The Court To Act As Lead Plaintiff Is July 23, 2012
    5. ViroPharma To Release 2012 Second Quarter Financial Results On August 9, 2012
    6. ViroPharma Incorporated Reports Second Quarter 2012 Financial Results
    7. ViroPharma to Present at the Stifel Nicolaus 2012 Healthcare Conference
    8. ViroPharma To Host Analyst And Investor Seminar On September 21, 2012
    9. ViroPharma Incorporated Reports Third Quarter 2012 Financial Results
    10. ViroPharma Launches Novel Campaign to Illustrate the Emotional Burden of Hereditary Angioedema
    11. ViroPharma To Participate In Two Upcoming Healthcare Investor Conferences
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... the leading health care supply chain expertise, analytics and ... national contracts that expand its portfolio to provide hospital ... These include manufacturer product and service agreements, as well ... IT consulting support. New Novation agreements ...
    (Date:1/15/2014)... 15, 2014 Shire plc (LSE: SHP, NASDAQ: ... Fair Trading (OFT) approval condition to the announced tender offer for ... As a result of the waiver, the transaction is ... the tender offer on January 24, 2014 following the currently scheduled ...
    (Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers and distributors ... able to protect their most important business assets, ... ) Because of the highly-competitive ... remains one of the most litigious industry sectors ...
    Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Intellectual Property Insurance for Medical-related Products and Services 2
    ... 26, 2011 Masimo (NASDAQ: MASI ) today ... Goldman Sachs 32nd Annual Global Healthcare Conference at Terranea in ... 8:40 a.m. Pacific Time.  A live audiocast of the presentation ... .  A replay of the audiocast will be available following ...
    ... OTC Markets Group Inc. (OTCQX: OTCM), ... the world,s largest electronic marketplace for broker-dealers to trade ... (TSX.V: VRS; OTCQX: VRSEF), a medical device company ... of cancer, is now trading on the OTC market,s ...
    Cached Medicine Technology:Masimo to Present at Goldman Sachs 32nd Annual Global Healthcare Conference 2Verisante Technology Inc. Joins OTCQX 2
    (Date:4/24/2014)... more than 15 years ago, the PTEN gene has ... the onset and progression of numerous cancers. Consequently, when ... grow unchecked and cancer can develop. , Now a ... Center (BIDMC) helps explain more precisely how PTEN exerts ... can set cells on a cancerous course. The new ...
    (Date:4/24/2014)... Benefits often coexist with the negative and stressful outcomes ... later diagnosed with a life-limiting illness, says a recent ... Waterloo. , While the challenges are numerous and life-changing ... who participated in the Waterloo-led research reported positive outcomes ... findings appear in the most recent issue of the ...
    (Date:4/24/2014)... the Center for BrainHealth will bring together national ... brain-related challenges at its inaugural Brain Health Summit, ... Featured speakers will include Dr. Sandra Bond Chapman, ... BrainHealth, U.S. Senator Chuck Grassley (R-IA), U.S. Representative ... Secretary for Policy and Early Learning, U.S. Department ...
    (Date:4/24/2014)... of prescription opioid overdose deaths was outlined yesterday in ... leaders of agencies in the U.S. Department of Health ... care providers to expand their use of medications to ... a number of misperceptions that have limited access to ... medications can be used in combination with behavior therapies ...
    (Date:4/24/2014)... one of 30 grants from the National Cancer Institute ... in its new National Clinical Trials Network ... investigators charged with distributing resources in a more effective ... reflects recommendations from a 2010 Institute of Medicine ... Faster design, launch, and completion of clinical ...
    Breaking Medicine News(10 mins):Health News:Surprising new insights into the PTEN tumor suppressor gene 2Health News:Surprising new insights into the PTEN tumor suppressor gene 3Health News:Parents of severely ill children see benefits as caregivers, says study 2Health News:Inaugural Brain Health Summit focuses on brain resilience and regeneration 2Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 2Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 3Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 4Health News:Dartmouth awarded lead role in NCI clinical trials network 2Health News:Dartmouth awarded lead role in NCI clinical trials network 3
    ... of the new health reform in China have been ... one of the most important policies ,The National Essential ... solve the high cost of drugs in China through ... drug prices that cover a wide range of diseases ...
    ... Million Contribution Mark to Support Families Living with Autism and Other ... ... -- Safeway (NYSE:SWY) captures Easter Seals, highest ... for children and adults with autism and other disabilities in 2009 ...
    ... celebrating their 50th year anniversary this month. Founded in 1959, ... various industries. In the 1970s, Key Instruments began focusing exclusively ... flow meters, and then expanded to include molded flow meters, ... ...
    ... tattoo to fit horizontal tummy tuck and c-section scars. It is made ... was designed to last 1-3 days. It can be applied and removed ... ... ScarArt, an innovative new company specializing in adhesive products used to conceal ...
    ... provide affordable and timely transcription services , ... ... Inc., the nation,s leading provider of transcription services to group ... will incorporate M*Modal,s Conversational Documentation Services (CDS) ...
    ... NuSil Technology announced a definitive agreement to acquire the pharmaceutical ... ... Carpinteria, Calif. (Vocus) May 21, 2009 -- NuSil ... silicone compounds for the healthcare and pharmaceutical industries, announced a ...
    Cached Medicine News:Health News:Frost & Sullivan Looks at the Influence of China's New Health Reform on the Pharmaceutical Market 2Health News:Frost & Sullivan Looks at the Influence of China's New Health Reform on the Pharmaceutical Market 3Health News:Safeway Earns Easter Seals' All-Time Top Corporate Partner Designation 2Health News:Safeway Earns Easter Seals' All-Time Top Corporate Partner Designation 3Health News:Safeway Earns Easter Seals' All-Time Top Corporate Partner Designation 4Health News:Key Instruments Celebrates 50 Year Anniversary 2Health News:Key Instruments Celebrates 50 Year Anniversary 3Health News:ScarArt -Creatively Camouflage Abdominal Scars 2Health News:MxSecure Expands Offerings with M*Modal Speech Recognition Solution 2Health News:MxSecure Expands Offerings with M*Modal Speech Recognition Solution 3Health News:NuSil Technology Acquires Pharmaceutical Antifoam (Simethicone) Business from Bluestar Silicones 2Health News:NuSil Technology Acquires Pharmaceutical Antifoam (Simethicone) Business from Bluestar Silicones 3
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    Medicine Products: